Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis

Population pharmacokinetics and Monte Carlo dosing simulations of intravenous piperacillin/tazobactam in patients on continuous ambulatory peritoneal dialysis with peritonitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220515001

Enrollment

Registered

2022-05-15

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on continuous ambulatory peritoneal dialysis with peritonitis Piperacillin/tazobactam, peritoneal dialysis, peritonitis, pharmacokinetics

Interventions

Patients on continuous ambulatory peritoneal dialysis age more than 18 years old with peritonitis who recieve intravenous piperacillin/tazobactam. A total of 8 blood samples and 8 dialysate samples a

Other

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients on continuous ambulatory peritoneal dialysis age more than 18 years old with peritonitis that be diagnosed when at least two of the following are present 1) clinical features consistent with peritonitis, that is,abdominal pain and/or cloudy dialysis effluent; 2) dialysis effluent white cell count > 100/mL (after a dwell time of at least 2 h), with > 50%polymorphonuclear leukocytes (PMN); 3) positive dialysis effluent culture, recieve intravenous piperacillin/tazobactam, able to give consent by themselves and are not enrolled another study

Exclusion criteria

Exclusion criteria: 1. Patients who received piperacillin/tazobactam within 24 hours ago. 2. Patients who on hemodialysis or continuous renal replacement therapy 3. Patients who had allergy history to Piperacillin, Tazobactam and beta-lactams 4. Septic shock 5. Pregnancy 6. Burn 7. Hemoglobin < 7 g%

Design outcomes

Primary

Measure	Time frame
Population pharmacokinetics of piperacillin and tazobactam in patient on continuous ambulatory peritoneal dialysis with peritonitis 24 hrs after piperacillin and tazobactam administration Population pharmacokinetics model	—

Secondary

Measure	Time frame
Probability of target attainment profile of intravenous piperacillin/tazobactam 24 hrs after piperacillin and tazobactam administration Monte Carlo simulation	—

Countries

Thailand

Contacts

Public ContactTAWEESAK MANEEROT

Prince of Songkla University

taweesak@pharmacy.psu.ac.th6674288871

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026